Navigation Links
Clearbridge BioMedics Achieves ISO 13485 Certification and Launches ClearCell (TM) System for Cancer Research Markets
Date:3/26/2012

SINGAPORE, March 26, 2012 /PRNewswire-Asia/ -- Clearbridge BioMedics has achieved ISO13485 certification for the development of cell-based in-vitro diagnostic devices and today launched its revolutionary ClearCell™ System, for the cancer research market. This is one of the world's first commercially-available systems that can successfully isolate circulating tumour cells (CTC) from blood, using biomechanical properties. The ClearCell™ System, which consists of the proprietary CTChip®, can retrieve intact and viable CTCs in their native states, without the use of antibodies or magnetic beads. This will enable cancer researchers to better understand the relationship between such cells and mechanisms of cancer. The ClearCell™ System will be on showcase at the American Association for Cancer Research annual meeting, from 31 March to 4 April 2012 in Chicago.

"Through our ClearCell™ System, we are now entering the diverse and growing cancer research market. This in turn will have an impact on improving new therapies for cancer patients. We are targeting cancer research organisations and hospitals, which regularly need to isolate and analyse CTCs. We believe that ClearCell™ will be of particular interest to the research community, since it can retrieve viable and intact cells. Moving forward, we are working towards the development of the ClearCell™ System for in-vitro diagnostic applications," said Johnson Chen, Co-Founder Clearbridge BioMedics.

ISO 13485 is a comprehensive management system for the design and manufacture of medical devices. This certification has become the model standard for the medical devices industry and Clearbridge BioMedics is one of the few companies, within the CTC sector, to have met this Quality Management System. By complying with this regulatory requirement, Clearbridge BioMedics demonstrates its commitment to rigorous product development standards.

The ClearCell™ System consists of the disposable, single-use CTChip®, and the ClearCell™ unit. CTCs isolated on the CTChip® can be stained directly on-chip for identification or retrieved for further analysis. ClearCell™ has a number of advantages making it relevant for the research sector. These include:

  • A first-in-class research use solution for the isolation, enumeration, staining and retrieval of CTCs.
  • Label-free isolation, allowing the heterogeneous CTC population to be captured in their viable and native states. This is ideal for research, as it allows for further downstream genetic analysis, such as single nucleotide polymorphisms and next generation sequencing.
  • Only a small volume of blood, approximately 2ml, is required for the system to effectively isolate CTCs
  • Real-time imaging, allowing researchers to monitor and observe the cell isolation process.

CTCs are cells that have detached from a primary tumour and are circulating in the bloodstream. These cells have been linked to metastasis and eventual morbidity. They are extremely rare, with only a few CTCs mixed with billions of blood cells per millilitre of blood. The fact that the ClearCell™ System can retrieve such cells demonstrates the sensitivity and accuracy of the device. In addition to being relevant to the research community, capturing and monitoring CTCs enables healthcare professionals to conduct cancer diagnosis, determine treatment options, measure treatment efficacy and post-cancer monitoring.

In addition to marketing the ClearCell™ System directly to the research community, Clearbridge BioMedics has partnered with Abnova, as a distributor of Clearbridge BioMedics' proprietary ClearCell™ unit and CTChip®.

About Clearbridge BioMedics
Clearbridge BioMedics specializes in novel platforms with applications in oncology research and diagnostics. It is a National University of Singapore (NUS) spinoff company that is committed to developing medical devices, which will impact the world and revolutionize cancer diagnostics and patient care, by leveraging on ground-breaking technology from research partners.

The ClearCell™ System comprises patent-pending CTChips®, which are microfluidic biochips able to effectively detect and isolate wholly-intact CTCs (Circulating Tumor Cells) from small quantities of patient blood samples. The isolated CTCs can then be stained directly on the CTChips® for identification and enumeration, or retrieved for further molecular analysis. The ClearCell™ System aims to be the next generation of non-invasive "liquid biopsy" approach for cancer screening, diagnosis, staging, personalised medication, and treatment monitoring. Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America. (www.clearbridgebiomedics.com)


'/>"/>
SOURCE Clearbridge BioMedics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Clearbridge BioLoc Unveils Innovative Lab-on-Card Analysis Platform for Point-of-Care Testing at Worlds Largest Clinical Lab Conference
2. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
3. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
4. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
5. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
6. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
7. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
8. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
9. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
10. Bionomics Achieves US$1 Million Milestone Payment from Genmab
11. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... Sept. 19, 2017   ZirMed Inc ., a recognized ... announced that it has been ranked #1 by its users ... Rankings 2017 User Survey. ZirMed was recognized as the ... hospitals and medical centers over 200 beds and holds one ... technology user survey history. ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)... YORK , Sept. 12, 2017   EcoVadis , the leading ... has published the first annual edition of its Global CSR Risk and ... companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 ... ... Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest ... the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity drive ... rare and deadly chromosome abnormality. , After struggling since birth with several health ...
(Date:10/13/2017)... ... , ... While it’s often important to take certain medications during the night, ... has identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX ... eliminates the need to turn on a light when taking medication during the night, ...
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... CT (PRWEB) , ... October 13, 2017 , ... ... long-term care services, staged a mock evacuation of the facility as part of a ... Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
Breaking Medicine News(10 mins):